Compass Therapeutics (NASDAQ:CMPX) Announces Earnings Results

Compass Therapeutics (NASDAQ:CMPX) announced its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01), Zacks reports.

Compass Therapeutics Stock Performance

NASDAQ:CMPX traded up $0.09 during mid-day trading on Friday, reaching $3.01. The stock had a trading volume of 204,038 shares, compared to its average volume of 1,941,835. Compass Therapeutics has a one year low of $0.76 and a one year high of $4.08. The firm has a 50 day moving average price of $2.56 and a two-hundred day moving average price of $1.93. The stock has a market capitalization of $413.87 million, a P/E ratio of -8.12 and a beta of 1.17.

Wall Street Analysts Forecast Growth

CMPX has been the subject of several research reports. Guggenheim started coverage on Compass Therapeutics in a report on Monday. They set a “buy” rating and a $12.00 price objective for the company. Piper Sandler began coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target on the stock. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, Jefferies Financial Group upped their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.38.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.